More targeted, less toxic: The golden future of cancer treatment.

By | September 10, 2019

Research of RMIT University shows that new synthetic molecules are up to 24 times more effective at killing cancer cells than a widely-used cancer drug and they’re built with resistance-fighting features to keep them effective over time, unlike current chemotherapies. Pre-clinical studies show the molecules are promising candidates for development into a new class of gold-based drugs that can wipe out cancer without destroying healthy cells.

Researchers have engineered gold-based molecules that target cancer cells and leave healthy cells unharmed, it is a critical step towards precision in cancer drugs with fewer toxic side effects.

The limitations of unremarkably used metal-based chemotherapies drove a requirement to search out higher alternatives. The disease kills over 9.6 million people globally each year and still remains the world’s second leading cause of death.

The metal-based drugs have successfully pushed survival rates up but their effectiveness is limited because of toxic side effects, drug resistance, and poor stability. The gold-based molecules that are designed are more selective and stable.

There’s incredible potential for the development of new cancer-fighting therapeutics that can deliver lasting power and precision.

The molecules were evaluated in pre-clinical tests and located to be extremely cytotoxic against prostate, breast, cervical, skin cancer and carcinoma cells. Animal trials showed treatment with the molecules considerably inhibited tumor growth gold-based compounds conjointly inhibit the action of associate catalyst found in cancer cells, thioredoxin enzyme, that’s coupled with cancer progression and therefore the development of drug resistance.

In addition, the molecules have robust medicinal drug properties, giving them a twin therapeutic impact and potential application within the treatment of chronic inflammatory conditions like an inflammatory disease